Johnson & Johnson's Biosense Webster unit already is the exclusive distributor of Coherex Medical Inc.'s WaveCrest left atrial appendage occlusion system outside of the US, but the heart-rhythm device business now says it is acquiring the Coherex outright, expanding its commitment to the LAA closure space for reducing stroke in atrial fibrillation patients.
J&J Enters LAA Closure Market In Earnest With Coherex Buy
Johnson & Johnson's Biosense Webster unit already is the exclusive distributor of Coherex Medical Inc.'s WaveCrest left atrial appendage occlusion system outside of the US, but the heart-rhythm device business now says it is acquiring the Coherex outright, expanding its commitment to the LAA closure space for reducing stroke in atrial fibrillation patients.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
• By
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
• By
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
More from Medtech Insight
• By
Swiss medtech exporters seek urgent diplomatic action from the Swiss Federal Council in a bid to overturn the 2 April US decision to put tariffs on goods imports.
• By
Beyond the US market, Monogram is actively pursuing regulatory approvals abroad, with India as a key target. The company has partnered with Shalby Hospitals, one of India’s largest orthopedic hospital networks, to conduct clinical trials and accelerate regulatory clearance in the region.
